STOCKS TELEGRAPH

Tag: Nexalin Technology

  • 3 Stocks That Could See Big Moves: Creative Medical Technology (CELZ), Cardiol Therapeutics (CRDL), Nexalin Technology (NXL)

    3 Stocks That Could See Big Moves: Creative Medical Technology (CELZ), Cardiol Therapeutics (CRDL), Nexalin Technology (NXL)

    The biotechnology industry remains characterized by a steady flow of research-driven updates, including trial expansions, protocol refinements, and regulatory communications. Each of these elements can contribute to shifting expectations around a therapy’s future viability. As companies move deeper into late-stage studies, the market increasingly weighs the probability of success against the remaining development risk.

    Creative Medical Technology Holdings Inc (CELZ)

    Creative Medical Technology Holdings Inc (NASDAQ: CELZ) started the day on May 08, 2026, with a 0.87% price increase to $2.31. During the day, the stock rose to $2.38 and sank to $2.10. Taking a long-term approach, CELZ posted a 52-week range of $1.50-$6.25.

    The Healthcare Sector giants’ yearly sales growth during the last 5-year period was 66.83%. Meanwhile, its Annual Earnings per share during the time was 66.83%.  Nevertheless, the stock’s Earnings Per Share (EPS) this year is 37.70%. This publicly-traded company’s shares outstanding now amount to $3.70 million, simultaneously with a float of $3.66 million. The organization now has a market capitalization of $8.54 million.

    Cardiol Therapeutics Inc. (CRDL)

    Cardiol Therapeutics Inc. (NASDAQ: CRDL) is continuing to expand its cardiovascular development platform by targeting inflammatory heart diseases with limited treatment options. Beyond recurrent pericarditis, the company is building clinical evidence in acute myocarditis, a serious condition that can lead to long-term cardiac complications and currently lacks targeted therapies.

    Market Momentum

    As of May 8, 2026, CRDL closed at $1.32, up 1.54%, with trading volume reaching 578,846 shares compared to an average volume of 686,648 shares. The company maintains a market capitalization of $147.418M and a beta of 0.43, reflecting relatively stable trading characteristics for a clinical-stage biotech company. Shares continue to trade within their 52-week range of $0.8800 to $1.71, while the 1-year target estimate of $7.40 highlights substantial upside potential tied to future clinical execution.

    Clinical Expansion: ARCHER Study

    Cardiol’s Phase II ARCHER study evaluated CardiolRx™ in patients with acute myocarditis, a condition involving inflammation of the heart muscle that can progress to heart failure or arrhythmias. The study demonstrated reductions in cardiac inflammation along with structural improvements, including decreases in left ventricular mass, an important marker associated with cardiac remodeling and recovery.

    Scientific and Strategic Relevance

    The recent announcement that CardiolRx™ Phase II pericarditis results will be published in the Journal of the American Heart Association adds broader scientific credibility to the company’s anti-inflammatory platform. Positive findings across multiple inflammatory cardiac conditions may strengthen confidence in the therapeutic potential of CardiolRx™ beyond a single indication.

    Outlook

    As Cardiol advances development across multiple cardiovascular diseases, successful clinical validation in myocarditis could meaningfully expand the company’s long-term commercial opportunity and reinforce its broader pipeline strategy.

    Nexalin Technology Inc (NXL)

    As of May 08, 2026, Nexalin Technology Inc (NASDAQ: NXL) got off with the flyer as it spiked 2.44% to $0.35. During the day, the stock rose to $0.36 and sank to $0.35. Taking a more long-term approach, NXL posted a 52-week range of $0.33-$2.00.

    In the past 5-year timespan, the Healthcare sector firm’s annual sales growth was -1.42%. Meanwhile, its Annual Earnings per share during the time were -1.42%.  Nevertheless, the stock’s Earnings Per Share (EPS) this year is 30.00%. This publicly-traded company’s shares outstanding now amount to $20.58 million, simultaneously with a float of $16.33 million. The organization now has a market capitalization of $7.25 million.

  • Significant Stock Increase For Nexalin (NXL) After Alzheimer’s Study Announcement

    Significant Stock Increase For Nexalin (NXL) After Alzheimer’s Study Announcement

    Nexalin Technology, Inc. (NASDAQ: NXL) stock is on a notable surge this current session, following the announcement of a pivotal study. As of the latest check, NXL shares were trading 19.55% higher on the US stock charts at $2.63. This positive market response underscores the potential impact of the company’s groundbreaking research.

    Innovative Research Publication

    Nexalin (NXL) did a research titled “Altered Neuronal Activity Patterns of the Prefrontal Cortex in Alzheimer’s Disease After Transcranial Alternating Current Stimulation (tACS): A Resting-State Functional Magnetic Resonance Imaging Study,” which was published in the Journal of Alzheimer’s Disease.

    This study builds on earlier results from Nexalin’s Deep Intracranial Frequency Stimulation (DIFS) studies by confirming the efficacy of non-invasive neurostimulation techniques in enhancing cognitive function in individuals with moderate Alzheimer’s disease (AD).

    Research Methods and Results

    Over the course of 30 one-hour sessions spread over three weeks, 46 participants were randomly randomized to receive either a placebo or actual DIFS treatment. The study used resting-state functional magnetic resonance imaging (rs-fMRI) to track changes in brain activity.

    The findings showed that Nexalin’s exclusive DIFS technology had a major impact on neuronal activity in important brain areas, establishing it as a secure, non-pharmacological therapy option for Alzheimer’s.

    Addressing a Global Challenge

    While existing treatments primarily alleviate symptoms, Nexalin’s DIFS technology demonstrates the capacity to modulate brain activity and restore metabolic functions, paving the way for potentially transformative treatments. The recent findings bolster NXL’s commitment to improving cognitive outcomes, emphasizing that DIFS not only enhances mental function but also exhibits favorable tolerability, even in elderly populations.

    By linking brain activity with blood flow and glucose metabolism, DIFS may address some of the core causes of cognitive decline in Alzheimer’s patients, offering hope for sustained cognitive improvement. This study represents a significant step forward for Nexalin’s DIFS technology, reinforcing the promise of non-invasive brain stimulation in the treatment of Alzheimer’s disease.

  • Pre-Market Gains For Nexalin (NXL) Driven By Upcoming Clinical Trial

    Pre-Market Gains For Nexalin (NXL) Driven By Upcoming Clinical Trial

    In the realm of financial markets, Nexalin Technology, Inc. (NASDAQ: NXL) is currently witnessing a remarkable upward trajectory in its stock performance. As of the most recent pre-market check, NXL stock rose 12.55% to $2.42 after closing at a noteworthy $2.15 the day before, a significant 57.51% rise. The company’s announcement of an upcoming clinical study is largely responsible for this optimistic increase in share price, since it has greatly increased investor confidence.

    Collaborative Clinical Trial Program

    Nexalin (NXL) announced this week that it will be partnering with the University of California, San Diego (UCSD) to launch a new clinical trial. UCSD senior scientist Dr. Ming Xiong Huang plans to use his affiliation with the San Diego VA to recruit patients with traumatic brain injury (TBI).

    The trial aims to assess the efficacy of Nexalin’s cutting-edge Gen-3 Halo headset within a virtual clinic framework, enabling patients to receive treatment from the comfort of their homes. This innovative approach seeks to mitigate the challenges and stigma often associated with visiting psychiatric offices or VA hospitals.

    Advancements in Treatment Technology

    The Gen-3 Halo headset is engineered with Nexalin’s proprietary Deep Intracranial Frequency Stimulation (DIFS) technology, employing an advanced 15 milliamp waveform. Building on the success of prior trials involving the Gen-2 15 mAmp console device, the latest model promises enhanced convenience for at-home treatment while ensuring clinical accuracy.

    The upcoming study aims to replicate previous findings, which indicated significant improvements in MEG (magnetoencephalography) signals and alleviation of pain symptoms among mTBI patients.

    Alignment with Veteran Care Objectives

    Titled “MEG Study of the Transcranial Electrical Stimulation Treatment for Mild Traumatic Brain Injury using the Nexalin Halo Headset that Utilizes the Advanced 15 Milliamp Waveform,” the study will explore the impact of NXL’s Gen-3 Halo headset on brain function and symptom management in veterans.

    Notably, this initiative aligns with the Veterans Administration’s commitment to enhancing therapeutic telehealth services for veterans dealing with mTBI, as highlighted in their 2025 Professional Judgement Budget, which allocates over $17 billion for mental health services targeting veterans.

  • Nexalin (NXL) Sees Significant Stock Surge Following A Growth Insight

    Nexalin (NXL) Sees Significant Stock Surge Following A Growth Insight

    After the company’s CEO participated in a notable interview, shares of Nexalin Technology, Inc. (NASDAQ: NXL) experienced a continued surge in the US stock market. During the extended trading session, NXL stock soared by 50.00% to $1.56, building on the regular-session rally that saw an increase of 37.77%, closing at $1.04.

    CEO’s Insight On Innovative Technology

    The interview with Nexalin, featured on the RedChip Small Stocks, Big Money show, aired last Saturday. Mark White, CEO of Nexalin, gave a company update in this exclusive interview on Bloomberg TV. Nexalin is leading the way in the revolutionary treatment of mental health issues with to its cutting-edge, non-invasive neurostimulation technology.

    By concentrating on deep brain stimulation, Nexalin’s devices, especially the state-of-the-art Gen-3 HALO Clarity, present a revolutionary alternative to conventional pharmacological treatments. This technology has demonstrated clinically significant improvements in treating conditions such as insomnia, PTSD, and traumatic brain injuries—afflictions that impact millions yet have limited effective treatments—positioning Nexalin as a burgeoning leader in a market projected to reach $537 billion by 2030.

    Expansion Into New Markets

    The Brazilian Health Regulatory Agency, the government organization in charge of approving new medications and medical devices in Brazil, has granted regulatory clearance to Nexalin’s second-generation (Gen-2), 15 milliampere (mA) neurostimulation device.

    Two regulatory licenses have been granted to Nexalin outside of China since the beginning of the year; the second being for the commercialization of its Gen-2 neurostimulation device in Brazil. With more than 215 million people living there and the ninth-largest economy in the world, Brazil is a significant market.

    Over 35 million people in this group have mental health issues. This approval serves as a crucial entry point into other South American markets. Nexalin is actively progressing in discussions with a key distributor in this region and anticipates providing further updates soon.